Ventana Recommends Shareholders to Defer Taking Any Action in Response to Roche Offer

Chat real-time with other investors about this VMSI news release, by clicking this link: http://www.stockwire.com/VMSI
 
  The Board of Directors of Ventana Medical Systems (NASDAQ: VMSI) today   recommended that its shareholders take no action at this time in response to the   announcement by Roche that it will make an unsolicited tender offer to acquire   all outstanding shares of Ventana for $75.00 in cash per common share.   Consistent with its fiduciary duties, and in consultation with its independent   financial and legal advisors, the company's Board will review and consider   Roche's offer and, following the commencement of the tender offer, will make a   recommendation to shareholders within 10 business days.
 
  Merrill Lynch   & Co. is acting as financial advisor and Sidley Austin LLP is acting as a   legal advisor to Ventana.
 
  About Ventana
 
  Ventana develops,   manufactures, and markets instrument/reagent systems that automate slide   preparation and staining in clinical histology and drug discovery laboratories   worldwide. Ventana's clinical systems are important tools used in the diagnosis   and treatment of cancer and infectious diseases. Ventana's drug discovery   systems are used to accelerate the discovery of new drug targets and evaluate   the safety of new drug compounds.
 
  Visit the Ventana Medical Systems,   Inc., website at www.ventanamed.com.
 
  During pre-market trading shares   are up 49% to $77.44.
 
  As the saying goes...follow the money!

To see the complete Movers & Shakers Blog go to:  http://www.stockwire.com .

About Stockwire:
Stockwire is a company that is pioneering a new way to  research companies before you invest them. It's called a Stockumentary. A  Stockumentary is a documentary on a publicly traded company. Imagine a Dateline  NBC segment, but on a publicly traded company. We are the first company to ever  bring this type of quality research to investors in this format.